Kornimate/medical-research-clean huggingface dataset:
the bone-myoregulation reflex and development of sarcopenia in osteoporosis

Conditions: Sarcopenia; Osteoporosis

Summary: bone and skeletal muscle are in a single unit that interacts with each other structurally and functionally. the aim of this study is to determine the contribution of bone myoregulation reflex as a neuronal crosstalk mechanism on the development of sarcopenia in postmenopausal and senile osteoporosis

bone and skeletal muscle are in a single unit that interacts with each other structurally and functionally. while myokines synthesized and released in skeletal muscle modulate the bone formation and destruction process, osteokines synthesized and released by bone cells have positive or negative effects on muscle (4,5,6,7,8,9). in addition to humoral crosstalk mechanisms between muscle and bone, there is also a neuronal crosstalk mechanism defined as bone myoregulation reflex. the aim of this study is to determine the contribution of bone myoregulation reflex as a neuronal crosstalk mechanism on the development of sarcopenia in postmenopausal and senile osteoporosis (10,11,12,13,14). osteoporotic cases would be determined by standard dxa measurements. the vibration will be applied with the powerplate® pro5 whole-body vibration (london uk) device. the vibration amplitude will be 2 mm. the vibration frequency will be 30, 33, and 36 hz. each vibration frequency will be applied for 45 seconds. a 5-second rest period will be applied between vibrations of 45 seconds. surface emg recordings will be taken from the right soleus muscle using the bipolar technique. a pair of self-adhesive ag/agcl (redline®) electrodes will be adhered to the skin according to the seniam protocol(2). recordings will be taken in the 1-500 hz frequency band. surface electromyography (emg) recordings will be taken with a powerlab ® (adinstruments, oxford, uk) data recorder with a sample rate of 20 khz. emg recordings will be analyzed offline with labchart7 pro® version 7.3.8 (adinstruments, oxford, uk). the acceleration measurement data will be recorded with the powerlab (adinstrument london) data acquisition simultaneously with the emg recording. acceleration recording will be made with a sample rate of 20 khz.

Eligibility criteria:
inclusion criteria: * for healthy young adults control healthy volunteers aged 20-45 years * for postmenopausal osteoporosis hip dxa t-score (neck or total hip) \< -2.5 * for the senile osteoporosis over 65 years male hip dxa t-score (neck or total hip) \< -2.5 female exclusion criteria: * osteopenic cases * possible sarcopenia (according to ewgsop2 criteria) * vertigo * kidney stone * panic attack story * secondary osteoporosis * those with polyneuropathy, central nervous system disease clinic/history * myopathies (steroid, vitamin d deficiency, primary muscle diseases, etc.) * cases with lesions on the soleus skin * history of fracture in lower extremity, joint prosthesis * lower extremity active/acute thrombophlebitis

Keywords: muscle strength bone mineral density
impact of covid-19 pandemic on single-stage laparoscopic cholecystectomy and laparoscopic common bile duct exploration service

Conditions: Gallstone

Summary: choledocholithiasis is reported to be present in 15-20% of patients with symptomatic gallstones. the single-stage management consists of performing either laparoscopic common bile duct exploration (lcbde) or intraoperative endoscopic retrograde cholangiopancreatography (ercp) at the same time as laparoscopic cholecystectomy (lc). since the coronavirus (covid-19) pandemic, surgical practice has significantly been impacted. the pandemic has had ramifications on patient and staff safety, surgical techniques, minimally invasive procedures, theatre workflow, education and training. we analysed a series of lcbde procedures in our institution pre-, intra- and post-covid-19 pandemic to assess the feasibility, efficacy and safety of this single-stage treatment approach following the pandemic.


Eligibility criteria:
inclusion criteria: * patients that underwent single-stage lc + lcbde for the management of choledocholithiasis with concomitant gallstones. exclusion criteria: * patients that underwent lc only or lcbde only
impact of prems in the shared decision process for renal replacement treatment methods.

Conditions: Chronic Kidney Disease, Stage 4 (Severe); Chronic Kidney Disease, Stage 5

Summary: the french "my health 2022" plan is the first bundled payment initiative for stage 4 and 5 chronic kidney disease (ckd) pathway with the aim to improve the quality of care and promote a multi professional collaboration for a more holistic approach of healthcare. renal replacement therapies (rrt) have a significant impact on the quality of life and autonomy of patients and their caregivers. the transition to these treatments is a critical point in the pathway, involving a complex choice for patients that cannot be based solely on medical considerations but requires to assess the needs and preferences of patients and their caregivers in order to improve their experience and the quality of care. the investigators propose to conduct a prospective cohort study aimed at 1/ describing the patient and caregiver experience, patient related outcome measures (prom) and the quality of life in relation to the decision-making process 2/ identifying the individual factors (socio-cultural, health literacy) associated with the patient experience, 3/ assessing the expectations and needs of patients regarding the information and support received during the process, and 4/ describing the perceptions of caregivers and professionals regarding the information provided and the decision-making process. the assessments will be conducted by questionnaires before, 3 months after the information on rrt and 3 months after the initiation of rrt or 24 months after the initial information for patients and caregivers and at the time of information on rrt for professionals. the data from the questionnaires will be further explored by a qualitative survey in a subgroup of patients and caregivers. the results of this study will help identify the factors determining the choice and satisfaction of patients and their caregivers in order to adapt the decision making support and thus have a patient-centered approach.


Eligibility criteria:
inclusion criteria: patients * stage 4-5 chronic kidney disease not on dialysis with a nephrologist follow up \>3 months * glomerular filtration rate estimated by the ckd epi formula \< 20 ml/min/1.73 m2, * referred for consultation and information on renal replacement therapies. * age \>18 years old. * patient with a sufficient level of oral comprehension of french, able to understand the research exclusion criteria: * significant cognitive disorders preventing decision making * patients under guardianship, or legal protection * referred for ultrafiltration in the context of cardio renal syndrome

Keywords: chronic kidney disease renal replacement therapy, caregivers prem prom shared decision making
a single ascending dose study of safety and tolerability of sta363 compared to placebo in 15 patients with chronic discogenic low back pain

Conditions: Low Back Pain

Summary: a phase i, randomized, double-blinded, placebo-controlled, single ascending dose study to investigate the safety, local tolerability and transformation of nucleus pulposus following intradiscal injection of sta363 or placebo in patients with discogenic low back pain. 15 patients will participate in either of 3 dose groups, each comprising 5 patients: * group 1: sta363 dose 1 (3 patients) or placebo (2 patients) * group 2: sta363 dose 2 (3 patients) or placebo (2 patients) * group 3: sta363 dose 3 (3 patients) or placebo (2 patients)


Eligibility criteria:
inclusion criteria: * signed informed consent prior to any study-related procedures * chronic discogenic low back pain present for more than 6 months prior to the screening visit * 20 to 60 years of age at the screening visit * insufficient response to at least 6 months of non-operative treatment (analgesics and/or antiinflammatory medication, physiotherapy etc.) * a single lumbar disc appropriate for treatment at l3/4 to l5/s1, based on clinical evaluation by the investigator * pfirrmann grade ii-iii * ability to understand the written and verbal information about the study exclusion criteria: * treatment with any investigational product within 3 months prior to the screening visit * more than one painful intervertebral disc * a painful intervertebral disc above l3/4 level * current infection or prior history of spinal infection (e.g., discitis, septic arthritis, epidural abscess) or an active systemic infection * previous lumbar spine surgery * previous disc invasive treatment procedures at the affected level(s) (e.g., intradiscal electrothermal therapy, intradiscal radiofrequency thermocoagulation) * pfirrmann grade i, iv and v * evidence of prior lumbar vertebral body fracture or trauma * need for spinal decompression assessed by the investigator * presence of disc extrusion or sequestration * patients previously included in the study * patients suffering from psychosomatic pain in the opinion of the investigator * referred leg pain of compressive origin * known alcohol and/or drug abuse * severe intercurrent illness (e.g. rheumatic disease or chronic pain syndrome) or concomitant treatment (e.g. immunosuppressive drugs), which, in the opinion of the investigator, may put the patient at risk when participating in the study, or affect the patient's ability to take part in the study * clinically significant abnormalities in clinical chemistry or haematology parameters as assessed by the investigator * pregnant or lactating females or intention to become pregnant within the study period * known allergy to any of the components of the drug product or placebo * known opioid allergy or intolerance * patients requiring treatment with warfarin or other anticoagulant therapy * unwillingness to refrain from treatment with non-steroidal anti-inflammatory drugs (nsaids) within 5 days before the planned study treatment * body weight less than 50 kg
a two part trial investigating the safety of nn9925 in healthy male subjects

Conditions: Diabetes; Diabetes Mellitus, Type 2; Healthy

Summary: this trial is conducted in europe. the aim of this trial is to investigate the safety, tolerability and bioavailability (exploring absorption of drug in body) of nn9925 in healthy male subjects.


Eligibility criteria:
inclusion criteria: * male subjects with good general health as judged by the physician * body weight of 65-95 kg (both inclusive) * body mass index (bmi) of 18.5-27.5 kg/m2 (both inclusive) exclusion criteria: * known or suspected allergy to trial product or related products * acute infection or inflammation or other illness that may confound the results of the trial or pose a risk to the subject by administering the trial product, as judged by the physician * presence of clinically significant acute gastrointestinal symptoms (e.g. nausea, vomiting, heartburn or diarrhoea) or malabsorptive states of disease (celiac disease, lactose intolerance or chronic pancreatitis), as judged by the physician
a feasibility registry of actigraphy monitoring in degenerative mitral regurgitation subjects receiving the mitraclip® device

Conditions: Mitral Regurgitation

Summary: a prospective, open-label, and multi-centered feasibility registry.

this is a prospective, open-label, and multi-centered feasibility registry (single arm study). approximately 36 subjects with prohibitive risk degenerative mitral regurgitation (dmr) who receive at least 1 commercial mitraclip will be registered at up to 10 us sites.

Eligibility criteria:
inclusion criteria: * subject must consent to receiving the mitraclip device * subject must consent, be able, and commit to wearing the actiwatch continuously for approximately 7 months * subject must consent to use of their data from this registry for purposes of exploratory research and publication and presentation exclusion criteria: * subject is not a member of vulnerable population * subject must not have any disabilities that preclude reliable data collection from the actiwatch, e.g., epilepsy with uncontrolled recurring episodes, serious stage degenerative/disabling disease (e.g. parkinson's disease), inability to walk or will require walking aids, etc.

Keywords: mitraclip structural heart failure degenerative mitral regurgitation (dmr) actigraphy
clinical evaluation of laminate veneers with coronal post versus post and core foundation restoration with single crown for restoration of endodontically treated anterior teeth (randomized controlled trial) "in-vivo study"

Conditions: Teeth, Endodontically-Treated; Anterior Teeth

Summary: clinical evaluation of laminate veneers with coronal post versus post and core foundation restoration with single crown for restoration of endodontically treated anterior teeth (randomized controlled trial) "in-vivo study"


Eligibility criteria:
inclusion criteria: 1. from 18-60 years old, should be able to read and sign the consent document. 2. ability to tolerate the restorative procedures (physical and psychological). 3. patients with anterior endodontically treated teeth indicated for coronal restoration: 1. good oral hygiene 2. minimum remaining coronal tooth height of 4 mm 3. normal functional occlusal stresses within physiological limits. 4. adequate crown/root ratio 5. no signs and symptoms related to active periapical pathosis or endodontic failure. 4. with no active periodontal or pulpal problems. 5. willing to return for follow-up visits. exclusion criteria: 1. teeth not fully erupted as in young patients. 2. poor oral hygiene and lack of motivation 3. vital teeth 4. psychiatric problems or unrealistic expectations 5. excessive parafunctional stresses and bad habits like nail biting. 11 6. the absence of sound enamel margins for the preparation 7. abnormally small teeth or with structural defects in enamel. 12 8. tooth mobility or inadequate crown/root ratio.

Keywords: endocrown laminate veneer with coronal post post and core crown
role of vitamin c infusion in postoperative mechanically ventilated neonates with sepsis

Conditions: Vitamin C; Postoperative; Mechanically Ventilation; Sepsis; Neonate

Summary: this study aims to evaluate the effect of intravenous vitamin c infusion on septic mechanically ventilated full-term neonates who underwent surgical interventions regarding mechanical ventilation parameters, time to wean, and the need for inotropic support.

neonatal sepsis is a syndrome featuring non-specific signs and symptoms of systemic infection accompanied by bacteremia in the first 28 days of extrauterine life. this condition is a public health problem that still contributes to mortality and morbidity in neonatal intensive care units (nicus) in high, as well as low- and middle-income countries. vitamins are essential micronutrients with key roles in many biological pathways relevant to sepsis. some of these relevant biological mechanisms include antioxidant and anti-inflammatory effects, protein and hormone synthesis, energy generation, and regulation of gene transcription. vitamin c, ascorbic acid, is a water-soluble essential micronutrient commonly found in plants, especially fruits. when absorbed, it dissociates at physiological ph to form ascorbate, the redox state of the vitamin most commonly found in cells. in addition to being a potent antioxidant, vitamin c is a cofactor for enzymes involved in protein and hormone synthesis, metabolic pathways for energy generation, and regulation of gene transcription.

Eligibility criteria:
inclusion criteria: * age more than 37 weeks. * both sexes. * neonates with sepsis are diagnosed both clinically and serologically after any surgical intervention. exclusion criteria: * major congenital anomalies and chromosomal abnormalities. * neonate \<37weeks gestation. * hypoxic ischemic encephalopathy (hie). * neuromuscular diseases. * intraventricular hemorrhage (iv hge).
quality of life of tep vs lichtenstein hernioplasty

Conditions: Inguinal Hernia

Summary: to determine if there is a difference in the quality of life in between patients who undergoes laparoscopic totally extra-peritoneal (tep) or modified lichtenstein hernioplasty

patients presenting with reducible inguinal hernias will be randomized between open or laparoscopic repair groups. the primary outcome will be the quality of life scores. patients will be followed-up for 12 months.

Eligibility criteria:
inclusion criteria: * 18 years of age and older * both genders * unilateral inguinal hernias * reducible inguinal hernias * elective setting exclusion criteria * asa physical status (american society of anaesthesiologists) grade \> 2 * recurrence * inguinal-scrotal hernias * prostatectomy, pfannenstiel incision, previous pre-peritoneal surgery * pregnancy * refusal for general anaesthesia
cognitive behavioral therapy for insomnia: face-to-face versus telemedicine

Conditions: Insomnia

Summary: the purpose of this study is to compare the effectiveness of cognitive-behavioral therapy (cbt) for insomnia conducted face-to-face with a therapist versus cbt for insomnia conducted using internet-based videoconference technology.

the objective of this clinical trial is to compare the effectiveness of telemedicine cognitive-behavioral therapy (cbt) for insomnia \[via the american academy of sleep medicine sleep telemedicine (aasm sleep tm) platform\] to gold standard face-to-face cbt for insomnia. the central hypothesis is that cbt for insomnia delivered by aasm sleeptm will be comparable to face-to-face cbt for insomnia for clinical outcomes and patient satisfaction, but aasm sleeptm will be a more cost effective treatment modality (primarily through reduced costs associated with facility use and patient time). the rationale for the proposed project is rooted in the critical need to disseminate cbt for insomnia using the most effective and efficient modalities, with recognition that therapist involvement likely produces the most favorable outcomes.

Eligibility criteria:
inclusion criteria: 1. current diagnosis of insomnia exclusion criteria: 1. suspicion of or inadequately treated sleep disorder other than insomnia 2. presence of psychiatric disorders for which cbt for insomnia may be contraindicated 3. unstable chronic medical condition directly related to insomnia 4. routine overnight shift work 5. previous failed adequate trial of cbt for insomnia 6. unstable dose of sleep medications 7. lack of access to reliable wifi connection in the home
shaping anesthetic techniques to reduce post-operative delirium

Conditions: Delirium; Lumbar Radiculopathy; Lumbar Osteoarthritis; Lumbar Spine Disc Degeneration

Summary: the purpose of this study is to determine if light sedation with spinal anesthesia reduces the incidence of delirium compared to receiving general anesthesia during spinal surgery in older adults.

post-operative delirium is a common occurrence in older adults. post -operative delirium has been associated with cognitive decline after hospitalization. developing perioperative management strategies to prevent delirium may also reduce potential cognitive decline in older adults after surgery. the choice and dose of anesthetic and sedative drugs are known risk factors in the development of delirium. excessive doses of anesthetic and sedation drugs during surgery have been associated with poor outcomes that occur after surgery. currently depth of anesthesia can be measured by an additional monitoring technique called bispectral index (bis). the purpose of this study is to determine if light sedation with spinal anesthesia reduces the incidence of delirium compared to receiving general anesthesia during spinal surgery in older adults. previous studies have shown that using light sedation and spinal anesthesia during surgery may reduce the incidence of delirium up to 50%.

Eligibility criteria:
inclusion criteria: * male or female patients age 65 and over. * patients undergoing lumbar fusion performed by dr. charles edwards ii, dr. charles edwards, dr. clayton dean , or dr. justin park at mercy medical center. * expected length of surgery \<3 hours. * ability to understand study procedures and to comply with them for the entire length of the study exclusion criteria: * contradictions to spinal anesthesia (severe aortic stenosis, anti-coagulant or antiplatelet medications, other) * body mass index \> 40 kg/m2 * prior lumbar fusion from l2-l5 in entirety * communication issues precluding delirium assessment or sedation * dementia or mini-mental status exam score \< 24 * psychiatric disease that would preclude cooperation with sedation with spinal anesthesia * any other reason that the attending anesthesiologist or surgeon feels that clinical circumstances dictate a strong preference for either spinal or general anesthesia. * inability or unwillingness of individual or legal guardian/representative to give written informed consent.

Keywords: delirium elderly lumbar surgery
hipec combined gastrectomy in patients with advanced gastric cancer received neoadjuvant chemotherapy

Conditions: Gastric Cancer; Peritoneal Metastases

Summary: patients with stage ct3-4n+m0 gastric cancer were recommended to receive neoadjuvant chemotherapy before radical surgery in terms of the eradication of micrometastasis in addition to local control, higher compliance with intensive chemotherapy, and avoidance of futile surgery by detection of initially invisible distant metastasis after rapid disease progression. however, in some studies, gastrectomy followed by neoadjuvant chemotherapy failed to demonstrate survival benefits for these patients. and peritoneal recurrence was the most common and devastating reason. hyperthermic intraperitoneal chemotherapy (hipec) was introduced for peritoneal cancer last century. a few studies suggested hipec could improve prognosis in patients with limited peritoneal metastasis from various cancer. in summary, we conducted this study to confirm the efficacy and safety of hipec after gastrectomy in patients with advanced gastric cancer received neoadjuvant chemotherapy.


Eligibility criteria:
inclusion criteria: * histologically proven adenocarcinoma of stomach * stage ct3-4n+m0 * no involvement of esophagus \> 3 cm * ecog (eastern cooperative oncology group) : 0\~1 * no previous chemotherapy or radiotherapy for any malignancy * no previous surgery for gc excluding endoscopic mucosal resection or endoscopic submucosal dissection * signed the informed consent form exclusion criteria: * serious diseases that are difficult to control * severe hepatic and renal dysfunction * abnormal coagulation * the presence of other serious physical or mental illness or laboratory abnormalities may increase the risk of participating in the study, or interfere with the results of the study, as well as the patients who the investigator believes are not suitable for participating in the study
tibola : multicenter descriptive study in eastern france

Conditions: TIBOLA; Rickettsia Infections

Summary: tibola (tick-borne lymphadenopathy) is a tick-borne disease. the pathogen is most often rickettsia (r. slovaca or r. raoultii), but other strict intracellular bacteria have been described (francisella tularensis, coxiella burnetii, bartonella hensenlae). transmitted by ticks (dermacentor), it is characterized by an inoculation eschar at the tick bite site, accompanied by painful loco-regional lymphadenopathy. it is most often a benign pathology, which can nevertheless leave sequellar alopecia or persistent asthenia. in spring 2021, an impression of increased cases was reported by clinicians in eastern france. the study aims to clarify the clinical-biological presentation and the evolution of the number of cases of tibola in this region between 2016 and 2021. at the same time, entomologists have noted an upsurge in this tick in certain biotopes in recent years.


Eligibility criteria:
inclusion criteria: * person, minor or major, * having been diagnosed with tibola * between january 1, 2016 and december 31, 2021 * at the university hospital of nancy or strasbourg in the departments of infectious and tropical diseases, dermatology, microbiology and pediatrics.

Keywords: dermacentor debonel